Shares of rare disease specialist Sarepta Therapeutics (NASDAQ: SRPT) rose by as much as 67.7% today on over ten times the average daily volume. What sent this mid-cap biotech stock into orbit?This monstrous rally was triggered by a positive interim data release for experimental gene therapy AAVrh74.MHCK7.micro-Dystrophin, which is designed to boost the levels of a key functional protein largely absent in the muscles of patients suffering from Duchenne muscular dystrophy (DMD). Image source: Getty Images.Continue reading